최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0143413 (2016-04-29) |
등록번호 | US-10082493 (2018-09-25) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 403 |
The present disclosure provides methods of processing data provided by a transcutaneous or subcutaneous analyte sensor utilizing different algorithms to strike a balance between signal responsiveness accompanied by signal noise and the introduction of error associated with that noise. The methods ut
The present disclosure provides methods of processing data provided by a transcutaneous or subcutaneous analyte sensor utilizing different algorithms to strike a balance between signal responsiveness accompanied by signal noise and the introduction of error associated with that noise. The methods utilize the strengths of a lag correction algorithm and a smoothing algorithm to optimize the quality and value of the resulting data (glucose concentrations and the rates of change in glucose concentrations) to a continuous glucose monitoring system. Also provided are systems and kits.
1. A method for monitoring an analyte using an analyte monitoring system including a data processing device and a drug delivery device, comprising: monitoring, using the data processing device of the analyte monitoring system, a data stream including a set of contiguous source data points related to
1. A method for monitoring an analyte using an analyte monitoring system including a data processing device and a drug delivery device, comprising: monitoring, using the data processing device of the analyte monitoring system, a data stream including a set of contiguous source data points related to a concentration of the analyte;providing, using the data processing device of the analyte monitoring system, one or more sets of maximum lag corrected signals from the set of contiguous source data points;providing, using the data processing device of the analyte monitoring system, a first one or more sets of maximum smoothed signals from the set of contiguous source data points, wherein each of the first one or more sets of maximum smoothed signals is generated utilizing a first smoothing algorithm;providing, using the data processing device of the analyte monitoring system, a second one or more sets of maximum smoothed signals from the set of contiguous source data points, wherein each of the second one or more sets of maximum smoothed signals is generated utilizing a second smoothing algorithm;determining, using the data processing device of the analyte monitoring system, the analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the first and second one or more sets of maximum smoothed signals, wherein more weight is placed on the one or more sets of maximum lag corrected signals to determine the analyte concentration;determining, using the data processing device of the analyte monitoring system, a rate of change in the analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the first and second one or more sets of maximum smoothed signals, wherein more weight is placed on the first and second one or more sets of maximum smoothed signals to determine the rate of change; anddelivering, using the drug delivery device of the analyte monitoring system, a drug based on the determined analyte concentration. 2. The method of claim 1, wherein each of the one or more sets of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points. 3. The method of claim 2, wherein providing the one or more sets of maximum lag corrected signals includes using parameters which minimize a correlation between an expected glucose error and the time derivative estimates and minimize a correlation between the expected glucose error and a pre-determined array of the historical source data points. 4. The method of claim 3, wherein providing the one or more sets of maximum lag corrected signals includes utilizing an aggressive lag correction algorithm, the lag correction algorithm configured to drive one or more of the correlation between the expected glucose error and the time derivative estimates or the correlation between the expected glucose error and the pre-determined array of the historical source data points to zero. 5. The method of claim 1, wherein the first smoothing algorithm and the second smoothing algorithm are different. 6. The method of claim 1, further comprising averaging the first one or more sets of maximum smoothed signals and the second one or more sets of maximum smoothed signals. 7. The method of claim 1, wherein the data stream is received from a transcutaneously positioned analyte sensor. 8. The method of claim 7, wherein the analyte sensor includes a plurality of electrodes including a working electrode comprising an analyte-responsive enzyme. 9. The method of claim 8, wherein the enzyme is bound to a polymer disposed on the working electrode. 10. The method of claim 8, wherein the working electrode comprises a mediator. 11. The method of claim 10, wherein the mediator is bound to a polymer disposed on the working electrode. 12. The method of claim 10, wherein the mediator is crosslinked with a polymer disposed on the working electrode. 13. The method of claim 7, wherein the analyte sensor includes a plurality of electrodes including a working electrode comprising a mediator. 14. The method of claim 13, wherein the mediator is bound to a polymer disposed on the working electrode. 15. The method of claim 13, wherein the mediator is crosslinked with a polymer disposed on the working electrode. 16. A system, comprising: an analyte sensor configured to be in contact with bodily fluid under a skin surface to monitor a concentration of an analyte;a data processing device operatively coupled to the analyte sensor, wherein the data processing device is configured to: monitor a data stream including a set of contiguous source data points related to the concentration of the analyte;provide one or more sets of maximum lag corrected signals from the set of contiguous source data points;provide a first one or more sets of maximum smoothed signals from the set of contiguous source data points, wherein each of the first one or more sets of maximum smoothed signals is generated utilizing a smoothing algorithm;provide a second one or more sets of maximum smoothed signals from the set of contiguous source data points, wherein each of the second one or more sets of maximum smoothed signals is generated utilizing a second smoothing algorithm;determine the analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the first and second one or more sets of maximum smoothed signals, wherein more weight is placed on the one or more sets of maximum lag corrected signals to determine the analyte concentration; anddetermine a rate of change in the analyte concentration utilizing a weighted combination of the one or more sets of maximum lag corrected signals and the first and second one or more sets of maximum smoothed signals, wherein more weight is placed on the first and second one or more sets of maximum smoothed signals to determine the rate of change; anda drug delivery device configured to deliver a drug based on the determined analyte concentration. 17. The system of claim 16, wherein each of the one or more sets of maximum lag corrected signals is generated utilizing correction terms based on time derivative estimates and historical source data points. 18. The system of claim 17, wherein the data processing device is configured to provide the one or more sets of maximum lag corrected signals using parameters which minimize a correlation between an expected glucose error and the time derivative estimates and minimize a correlation between the expected glucose error and a pre-determined array of the historical source data points. 19. The system of claim 16, wherein the analyte sensor includes a plurality of electrodes including a working electrode comprising an analyte-responsive enzyme. 20. The system of claim 16, wherein the analyte sensor includes a plurality of electrodes including a working electrode comprising a mediator.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.